Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
113.54
-5.97 (-5.00%)
At close: Sep 12, 2025, 4:00 PM EDT
115.00
+1.46 (1.29%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Repligen Employees
Repligen had 1,778 employees as of December 31, 2024. The number of employees decreased by 5 or -0.28% compared to the previous year.
Employees
1,778
Change (1Y)
-5
Growth (1Y)
-0.28%
Revenue / Employee
$379,053
Profits / Employee
-$7,777
Market Cap
6.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,778 | -5 | -0.28% |
Dec 31, 2023 | 1,783 | -242 | -11.95% |
Dec 31, 2022 | 2,025 | 173 | 9.34% |
Dec 31, 2021 | 1,852 | 724 | 64.18% |
Dec 31, 2020 | 1,128 | 367 | 48.23% |
Dec 31, 2019 | 761 | 213 | 38.87% |
Dec 31, 2018 | 548 | 72 | 15.13% |
Dec 31, 2017 | 476 | 240 | 101.69% |
Dec 31, 2016 | 236 | 68 | 40.48% |
Dec 31, 2015 | 168 | 32 | 23.53% |
Dec 31, 2014 | 136 | 20 | 17.24% |
Dec 31, 2013 | 116 | -4 | -3.33% |
Dec 31, 2012 | 120 | -17 | -12.41% |
Dec 31, 2011 | 137 | 69 | 101.47% |
May 6, 2010 | 68 | -1 | -1.45% |
May 31, 2009 | 69 | 13 | 23.21% |
May 27, 2008 | 56 | 11 | 24.44% |
Jun 30, 2007 | 45 | 2 | 4.65% |
Jun 6, 2006 | 43 | 6 | 16.22% |
Jun 7, 2005 | 37 | -3 | -7.50% |
Jun 7, 2004 | 40 | -4 | -9.09% |
May 15, 2003 | 44 | 5 | 12.82% |
May 15, 2002 | 39 | -1 | -2.50% |
May 15, 2001 | 40 | 13 | 48.15% |
May 15, 2000 | 27 | 3 | 12.50% |
May 15, 1999 | 24 | 0 | - |
May 29, 1998 | 24 | 4 | 20.00% |
May 15, 1997 | 20 | 5 | 33.33% |
Jun 14, 1996 | 15 | -89 | -85.58% |
Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RGEN News
- 9 days ago - Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 22 days ago - Repligen Corporation to Present at Upcoming September Conferences - GlobeNewsWire
- 4 weeks ago - Repligen Corporation: Still Navigating Through The Covid Cliff - Seeking Alpha
- 6 weeks ago - Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 - Benzinga
- 6 weeks ago - Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization - GlobeNewsWire
- 6 weeks ago - Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance - GlobeNewsWire